Ventyx Biosciences (VTYX) Competitors $2.74 -0.10 (-3.52%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.76 +0.02 (+0.88%) As of 07/11/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTYX vs. IOVA, ARVN, SAGE, AMLX, TBPH, ATAI, KROS, TLRY, MNMD, and ORGOShould you be buying Ventyx Biosciences stock or one of its competitors? The main competitors of Ventyx Biosciences include Iovance Biotherapeutics (IOVA), Arvinas (ARVN), Sage Therapeutics (SAGE), Amylyx Pharmaceuticals (AMLX), Theravance Biopharma (TBPH), atai Life Sciences (ATAI), Keros Therapeutics (KROS), Tilray Brands (TLRY), Mind Medicine (MindMed) (MNMD), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry. Ventyx Biosciences vs. Its Competitors Iovance Biotherapeutics Arvinas Sage Therapeutics Amylyx Pharmaceuticals Theravance Biopharma atai Life Sciences Keros Therapeutics Tilray Brands Mind Medicine (MindMed) Organogenesis Iovance Biotherapeutics (NASDAQ:IOVA) and Ventyx Biosciences (NASDAQ:VTYX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends. Which has higher earnings and valuation, IOVA or VTYX? Ventyx Biosciences has lower revenue, but higher earnings than Iovance Biotherapeutics. Ventyx Biosciences is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIovance Biotherapeutics$164.07M3.81-$372.18M-$1.24-1.51Ventyx BiosciencesN/AN/A-$135.12M-$1.75-1.57 Do analysts rate IOVA or VTYX? Iovance Biotherapeutics currently has a consensus price target of $12.22, suggesting a potential upside of 553.59%. Ventyx Biosciences has a consensus price target of $10.00, suggesting a potential upside of 264.96%. Given Iovance Biotherapeutics' higher probable upside, equities analysts clearly believe Iovance Biotherapeutics is more favorable than Ventyx Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iovance Biotherapeutics 0 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50Ventyx Biosciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Do institutionals & insiders believe in IOVA or VTYX? 77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 97.9% of Ventyx Biosciences shares are held by institutional investors. 10.3% of Iovance Biotherapeutics shares are held by company insiders. Comparatively, 14.5% of Ventyx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is IOVA or VTYX more profitable? Ventyx Biosciences has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -176.49%. Ventyx Biosciences' return on equity of -47.45% beat Iovance Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Iovance Biotherapeutics-176.49% -49.71% -39.18% Ventyx Biosciences N/A -47.45%-43.49% Which has more volatility & risk, IOVA or VTYX? Iovance Biotherapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Comparatively, Ventyx Biosciences has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Does the media favor IOVA or VTYX? In the previous week, Iovance Biotherapeutics had 42 more articles in the media than Ventyx Biosciences. MarketBeat recorded 44 mentions for Iovance Biotherapeutics and 2 mentions for Ventyx Biosciences. Ventyx Biosciences' average media sentiment score of 1.30 beat Iovance Biotherapeutics' score of 0.14 indicating that Ventyx Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 2 Very Positive mention(s) 1 Positive mention(s) 39 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ventyx Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryVentyx Biosciences beats Iovance Biotherapeutics on 8 of the 15 factors compared between the two stocks. Get Ventyx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTYX vs. The Competition Export to ExcelMetricVentyx BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$194.98M$2.94B$5.56B$9.11BDividend YieldN/A2.45%5.07%4.01%P/E Ratio-1.578.8121.2120.54Price / SalesN/A292.00432.0899.78Price / CashN/A42.1137.1257.67Price / Book0.767.638.045.49Net Income-$135.12M-$55.05M$3.19B$250.45M7 Day Performance30.23%8.43%3.63%4.79%1 Month Performance10.04%5.42%4.06%7.68%1 Year Performance7.03%2.03%30.02%16.43% Ventyx Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTYXVentyx Biosciences3.52 of 5 stars$2.74-3.5%$10.00+265.0%+10.9%$194.98MN/A-1.5730News CoverageIOVAIovance Biotherapeutics4.6867 of 5 stars$1.70-2.9%$12.22+619.0%-77.8%$584.39M$164.07M-1.37500Trending NewsARVNArvinas3.9376 of 5 stars$7.79-2.0%$20.29+160.5%-72.8%$580.28M$263.40M-11.80420Positive NewsSAGESage Therapeutics3.5881 of 5 stars$9.17-0.3%$8.93-2.6%-21.0%$576.11M$41.24M-1.58690Analyst DowngradeAMLXAmylyx Pharmaceuticals3.4295 of 5 stars$6.76+7.3%$11.00+62.7%+236.8%$561.59M-$1.27M-2.17200Analyst UpgradeTBPHTheravance Biopharma1.8361 of 5 stars$11.31+1.4%$16.60+46.8%+21.1%$557.52M$64.38M-9.58110News CoverageAnalyst DowngradeATAIatai Life Sciences3.2348 of 5 stars$2.75-0.7%$9.00+227.3%+79.5%$554.93M$310K-3.0280Gap UpHigh Trading VolumeKROSKeros Therapeutics1.9554 of 5 stars$13.40-0.4%$30.56+128.0%-68.6%$546.28M$3.55M-74.44100Positive NewsTLRYTilray Brands1.8987 of 5 stars$0.50-6.6%$1.92+280.7%-68.6%$542.20M$788.94M-0.482,650MNMDMind Medicine (MindMed)2.3146 of 5 stars$7.20+0.4%$25.50+254.2%+7.9%$541.72MN/A-5.5840Positive NewsORGOOrganogenesis4.4092 of 5 stars$4.25flat$6.00+41.2%+45.8%$539.13M$482.04M-25.00950Positive News Related Companies and Tools Related Companies Iovance Biotherapeutics Competitors Arvinas Competitors Sage Therapeutics Competitors Amylyx Pharmaceuticals Competitors Theravance Biopharma Competitors atai Life Sciences Competitors Keros Therapeutics Competitors Tilray Brands Competitors Mind Medicine (MindMed) Competitors Organogenesis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTYX) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ventyx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
